In her columns debut, Debbie Klein shares the story of her late husband Steve's idiopathic pulmonary fibrosis diagnosis.

LTI-03 was shown to reduce inflammation and scarring in lung tissue collected from IPF patients and analyzed in a lab, ...

GRI-0621, an experimental oral therapy for IPF, may stabilize lung function, according to an interim analysis of an ongoing ...

As she plans her return to university teaching, columnist Ann Reynoso realizes how PF has given her a range of new skills for ...

For columnist Sam Kirton, Pulmonary Fibrosis Awareness Month is an opportunity to tell others about his journey.

Columnist Sam Kirton thought he'd meticulously prepared for his vacation, with all his medications in store. Then an illness took him down.

The U.S. Food and Drug Administration (FDA) has granted breakthrough therapy designation to BMS-986278, Bristol Myers Squibb’s investigational therapy for progressive pulmonary fibrosis (PF).

For pulmonary fibrosis patients, lung transplant is often the best choice for extending life and improving quality of life. Because PF is a progressive disease with no current cure, the lungs ...

Besides medication that can help manage symptoms and slow the progression of pulmonary fibrosis (PF), there are other therapeutic strategies available that can help patients cope with the effects of ...

BMS-986020 is an anti-fibrotic drug being developed by Bristol-Myers Squibb, and is chemically a lysophosphatidic acid (LPA) receptor antagonist. The drug, an oral formulation, is in clinical trials ...

The U.S. Food and Drug Administration (FDA) has granted its orphan drug designation to Alentis Therapeutics’ antibody-based therapy lixudebart (ALE.F02) for idiopathic pulmonary fibrosis (IPF). Orphan ...